Friday, 15 Feb 2019

You are here

Kallikrein Inhibitor Lanadelumab Prevents Hereditary Angioedema Attacks

Hereditary angioedema is a rare autosomal dominant disorder due to C1 inhibitor deficiency (type I) or dysfunction (type II) that leads to dysregulated plasma kallikrein activity, excess bradykinin production, and unpredictable potentially life-threatening recurrent angioedema attacks. FDA approved lanadelumab (Takhzyro) is a monoclonal antibody that inhibits plasma kallikrein, and in this study demonstrates its ability to significantly prevent hereditary angioedema attacks.

There is a significant unmet need for effective therapy in hereditary angioedema as existing therapies have significant limitations and toxicities. 

This multicenter, randomized clinical trial included 125 patients with hereditary angioedema type I or II, who were randomiized 2:1 to lanadelumab or placebo for 26 weeks.  Subcutaneous lanadelumab was given as 150 mg every 4 weeks (n = 28) or 300 mg every 4 weeks (n = 29) or 300 mg every 2 weeks (n = 27).

A total of 90% of patients completed the study. Prior to randomization, the mean number of hereditary angioedema attacks per month ranged from 3.2 to 4.0 per month.

Lanadelumab reduced the mean attack rate by 73-87% compared to placebo.  The attack rates in this 26 week trial were:

  • placebo 1.97 attacks/month
  • lanadelumab 150-mg q 4 weeks 0.48 attacks/month
  • lanadelumab 300-mg  q 4 weeks 0.53 attacks/month
  • lanadelumab 300-mg q 2 weeks 0.26 attacks/month

The most common adverse events were injection site reactions (34.1% placebo, 52.4% lanadelumab) and dizziness (0% placebo, 6.0% lanadelumab).

These findings support the use of lanadelumab as a prophylactic therapy for hereditary angioedema. 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Stopping Biologics Before Joint Surgery: Is Earlier Better?

Withholding intravenous abatacept (Orencia) for longer than a month before hip or knee arthroplasty among patients with rheumatoid arthritis (RA) did not lower the risk for postoperative infection, a retrospective claims-based analysis found.

Biologic High Out of Pocket Costs for Medicare Patients

Specialty tier drugs, including biologics, accounts for nearly half of all medication spending by Medicare Part D patients. High out-of-pocket costs for these patients is a major concern. 

RheumNow Podcast – TNFs and the Inflammasome (1.25.19)

Dr Jack Cush reviews the news from the past week at RheumNow.com.

Smoking Doesn't Influence Rituximab Responses in Rheumatoid Arthritis

Alcohol, smoking and obesity have all been shown to influence the risk and activity of rheumatoid arthritis (RA) and may also influence response to therapy. This study assesssed whether smoking would influence response to rituximab (RTX) in RA. 

Anakinra for Acute Crystal-Induced Arthritis

A retrospective analysis of hospitalized patients who also had a gout and pseudogout attack shows that injections of anakinra (interleukin-1 receptor antagonist) were highly effective and safe in nearly three-quarters of patients.  

Through a medical records search they found 100 patients and 115 episodes between 2014-2017 who were treated with anakinra for crystal arthritis.